Aileron Therapeutics (formerly Renegade Therapeutics) is a biopharmaceutical company that was founded in 2005 to develop and advance a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. The ability to target and regulate these control points affords the unique opportunity to exploit potentially thousands of currently "undruggable" cellular targets with applications in all human diseases.
Aileronâ€™s proprietary technology locks peptides into their biologically active shape, mimicking the structures found in nature, and ultimately endows the peptide with unique properties, including efficient cell penetration, high affinity binding to large target protein surfaces and excellent stability within the body.
Funding Rounds (7) - $139.5MUpdate
|Date||Amount / Round||Valuation||Lead Investor||Investors|
|Oct, 2014||$33M / Series E||—||Aju IB Investment||7|
|Nov, 2013||$30M / Series E||—||—||6|
|Jan, 2013||$12M / Series D||—||—||6|
|Jun, 2009||$40M / Series D||—||6|
|Apr, 2008||$10.5M / Series C||—||—||2|
|Jun, 2007||$7M / Series B||—||—||2|
|Dec, 2006||$7M / Series A||—||2|
Current Team (4)Update
|May 3, 2016||PRNewswire Asia - WuXi Healthcare Ventures Appoints Renowned Life Science Entrepreneur, Gregory Verdine, Ph.D. as newest Venture Partner|
|Apr 14, 2016||Xconomy - East Coast Biotech Roundup: Intellia, What’s Hot, Cydan, Fog & More|
|Apr 13, 2016||Xconomy - With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets|
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - Discovering Nimbus.|
|Dec 11, 2015||Business Wire - Research and Markets: Growth Hormone Deficiency - Pipeline Review 2015|
|Aug 14, 2015||Business Wire - Research and Markets: Abdominal Obesity - Pipeline Review, H1 2015|
|Jul 16, 2015||Xconomy - Protagonist Nabs $40M, Eyes 1st Trial Of Oral Peptide In Gut Disease|
|Jun 9, 2015||Business Wire - Research and Markets: Lipodystrophy Therapeutics Pipeline Review, H1 2015 - 6 Companies & 6 Drug Profiles|
Aileron Therapeutics Inc.
281 Albany Street
Cambridge, Massachusetts 02139